Morbidity Rates With Reduced Mycophenolate Mofetil Dosage: A Single-Center Experience

Transplantation Proceedings

Volumn 38, Issue 9, 2006, Pages 2864-2865

  Kaushik, M ^a   Kay, M D ^a   Bagul, A ^a   Nicholson, M L ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TSUKUBAENOLIDE;

ACUTE GRAFT REJECTION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG INDUCED CANCER; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MORBIDITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; STEROID THERAPY; VIRUS INFECTION;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES;

EID: 33750965427     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.08.170     Document Type: Article

References (9)

1. Bullingham R.E.S., Nicholls A., and Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 28 (1996) 925
2. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345 (1995) 1321
3. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomised clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61 (1996) 1029
4. Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60 (1995) 225
5. Squifflet J.P., Backman L., Claesson K., et al. Dose optimisation of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveris renal transplant recipients. Transplantation 72 (2001) 63
6. Mourad M., Malaise J., Chaib E.D., et al. Corelation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 47 (2001) 88
7. Pelletier R.P., Akin E.B., Bumgardner G.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 17 (2003) 200
8. Miller J., Mendez R., Pirsch J.D., et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. Transplantation 69 (2000) 875
9. Knoll G.A., Mac Donald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381